FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912500408> ?p ?o ?g. }

• W2912500408 endingPage "110" @default.
• W2912500408 startingPage "103" @default.
• W2912500408 abstract "Bromodomain and extraterminal motif (BET) protein inhibition is a promising cancer treatment strategy, notably for targeting MYC- or BRD4-driven diseases. A first-in-human study investigated the safety, pharmacokinetics, maximum tolerated dose and recommended phase II dose of the BET inhibitor BAY 1238097 in patients with advanced malignancies.In this phase I, open-label, non-randomised, multicentre study, patients with cytologically or histologically confirmed advanced refractory malignancies received oral BAY 1238097 twice weekly in 21-day cycles using an adaptive dose-escalation design at a starting dose of 10 mg/week. Model-based dose-response analysis was performed to guide dose escalation. Safety, pharmacokinetics, pharmacodynamics and tumour response were evaluated.Eight patients were enrolled at three dose levels (10 mg/week, n = 3; 40 mg/week, n = 3; 80 mg/week, n = 2). Both patients receiving 80 mg/week had dose-limiting toxicities (DLTs) (grade 3 vomiting, grade 3 headache and grade 2/3 back pain). The most common adverse events were nausea, vomiting, headache, back pain and fatigue. Pharmacokinetic analysis indicated a linear dose response with increasing dose. Two patients displayed prolonged stable disease; no responses were observed. Biomarker evaluation of MYC and HEXIM1 expression demonstrated an emerging pharmacokinetic/pharmacodynamic relationship, with a trend towards decreased MYC and increased HEXIM1 expression in response to treatment.The study was prematurely terminated because of the occurrence of DLTs at a dose below targeted drug exposure. Pharmacokinetic modelling indicated that an alternate dosing schedule whereby DLTs could be avoided while reaching efficacious exposure was not feasible. Registration number: NCT02369029." @default.
• W2912500408 created "2019-02-21" @default.
• W2912500408 creator A5007680151 @default.
• W2912500408 creator A5008444865 @default.
• W2912500408 creator A5018588889 @default.
• W2912500408 creator A5021624793 @default.
• W2912500408 creator A5030811547 @default.
• W2912500408 creator A5043063954 @default.
• W2912500408 creator A5051430596 @default.
• W2912500408 creator A5064572702 @default.
• W2912500408 creator A5067201704 @default.
• W2912500408 creator A5075701156 @default.
• W2912500408 creator A5075978554 @default.
• W2912500408 creator A5090082356 @default.
• W2912500408 date "2019-03-01" @default.
• W2912500408 modified "2023-10-10" @default.
• W2912500408 title "First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity" @default.
• W2912500408 cites W2002395443 @default.
• W2912500408 cites W2041535798 @default.
• W2912500408 cites W2044439361 @default.
• W2912500408 cites W2057460011 @default.
• W2912500408 cites W2062968059 @default.
• W2912500408 cites W2074642772 @default.
• W2912500408 cites W2098991007 @default.
• W2912500408 cites W2104538433 @default.
• W2912500408 cites W2105391162 @default.
• W2912500408 cites W2109790992 @default.
• W2912500408 cites W2118428599 @default.
• W2912500408 cites W2120572492 @default.
• W2912500408 cites W2138428661 @default.
• W2912500408 cites W2153056550 @default.
• W2912500408 cites W2298793032 @default.
• W2912500408 cites W2411070120 @default.
• W2912500408 cites W2411964580 @default.
• W2912500408 cites W2477359025 @default.
• W2912500408 cites W2499644901 @default.
• W2912500408 cites W2503456027 @default.
• W2912500408 cites W2587935821 @default.
• W2912500408 cites W2617901375 @default.
• W2912500408 cites W2731003977 @default.
• W2912500408 cites W2738383040 @default.
• W2912500408 cites W2761312364 @default.
• W2912500408 doi "https://doi.org/10.1016/j.ejca.2018.12.020" @default.
• W2912500408 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30711772" @default.
• W2912500408 hasPublicationYear "2019" @default.
• W2912500408 type Work @default.
• W2912500408 sameAs 2912500408 @default.
• W2912500408 citedByCount "63" @default.
• W2912500408 countsByYear W29125004082019 @default.
• W2912500408 countsByYear W29125004082020 @default.
• W2912500408 countsByYear W29125004082021 @default.
• W2912500408 countsByYear W29125004082022 @default.
• W2912500408 countsByYear W29125004082023 @default.
• W2912500408 crossrefType "journal-article" @default.
• W2912500408 hasAuthorship W2912500408A5007680151 @default.
• W2912500408 hasAuthorship W2912500408A5008444865 @default.
• W2912500408 hasAuthorship W2912500408A5018588889 @default.
• W2912500408 hasAuthorship W2912500408A5021624793 @default.
• W2912500408 hasAuthorship W2912500408A5030811547 @default.
• W2912500408 hasAuthorship W2912500408A5043063954 @default.
• W2912500408 hasAuthorship W2912500408A5051430596 @default.
• W2912500408 hasAuthorship W2912500408A5064572702 @default.
• W2912500408 hasAuthorship W2912500408A5067201704 @default.
• W2912500408 hasAuthorship W2912500408A5075701156 @default.
• W2912500408 hasAuthorship W2912500408A5075978554 @default.
• W2912500408 hasAuthorship W2912500408A5090082356 @default.
• W2912500408 hasBestOaLocation W29125004081 @default.
• W2912500408 hasConcept C104317684 @default.
• W2912500408 hasConcept C111113717 @default.
• W2912500408 hasConcept C112705442 @default.
• W2912500408 hasConcept C119157956 @default.
• W2912500408 hasConcept C126322002 @default.
• W2912500408 hasConcept C143998085 @default.
• W2912500408 hasConcept C185592680 @default.
• W2912500408 hasConcept C197934379 @default.
• W2912500408 hasConcept C2777288759 @default.
• W2912500408 hasConcept C2780580376 @default.
• W2912500408 hasConcept C2780852908 @default.
• W2912500408 hasConcept C29730261 @default.
• W2912500408 hasConcept C55493867 @default.
• W2912500408 hasConcept C71924100 @default.
• W2912500408 hasConcept C74401373 @default.
• W2912500408 hasConcept C98274493 @default.
• W2912500408 hasConceptScore W2912500408C104317684 @default.
• W2912500408 hasConceptScore W2912500408C111113717 @default.
• W2912500408 hasConceptScore W2912500408C112705442 @default.
• W2912500408 hasConceptScore W2912500408C119157956 @default.
• W2912500408 hasConceptScore W2912500408C126322002 @default.
• W2912500408 hasConceptScore W2912500408C143998085 @default.
• W2912500408 hasConceptScore W2912500408C185592680 @default.
• W2912500408 hasConceptScore W2912500408C197934379 @default.
• W2912500408 hasConceptScore W2912500408C2777288759 @default.
• W2912500408 hasConceptScore W2912500408C2780580376 @default.
• W2912500408 hasConceptScore W2912500408C2780852908 @default.
• W2912500408 hasConceptScore W2912500408C29730261 @default.
• W2912500408 hasConceptScore W2912500408C55493867 @default.
• W2912500408 hasConceptScore W2912500408C71924100 @default.
• W2912500408 hasConceptScore W2912500408C74401373 @default.

• next